30 closest matches · ranked by relevance
Anal Intraepithelial Neoplasia (AIN) · High-grade Squamous Intraepithelial Lesions (HSIL)
Primary: Related Adverse Events — 1; 1 number of participants
HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions
Primary: Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL) — 19 participants w histological clearance
Anal Cancer · Neoplasm of Uncertain Malignant Potential · Nonneoplastic Condition
Primary: Complete Response Through 1 Year — 38; 16 participants
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Anal Cancer · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years
Anus Neoplasms
Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042
Anal Cancer · HIV Infection · Human Papilloma Virus Infection
Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants
High Grade Anal Canal Squamous Intraepithelial Neoplasia · Human Immunodeficiency Virus
Primary: Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life…
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Cervical Carcinoma · Cervical Intraepithelial Neoplasia Grade 2/3 · Stage 0 Cervical Cancer
Primary: Histologic Regression — 40; 34.1 percentage of participants
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Cervical Intraepithelial Neoplasia
Primary: Recurrence of Cervical Intraepithelial Neoplasia Among HIV-positive Women — 60; 37 Participants
Postoperative Pain
Primary: Analgesia/Nociception Index (ANI) — 73; 49 units on a scale
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Anal Neoplasm
Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633
Anal Cancer
Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants
Colonoscopy
Primary: Adenoma Detection — 63; 59 participants
Squamous Cell Carcinoma of Anal Canal
Primary: Objective Response Rate (ORR) — 13.8 percentage of participants
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months